The Chain Consists Of Two Or More Carbons Which Are Unsubtituted Or Have Acyclic Hydrocarbyl Substituents Only Patents (Class 514/654)
-
Patent number: 8912217Abstract: A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound wherein the amine containing pharmaceutical active compound is selected from the group consisting of racemic or single isomer ritalinic acid or phenethylamine derivatives and the drug substance has a physical form selected from amorphous and polymorphic.Type: GrantFiled: April 12, 2012Date of Patent: December 16, 2014Assignee: Pisgah Laboratories, Inc.Inventors: Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol
-
Publication number: 20140357667Abstract: Cerebral palsy impaired speech in children and adolescents are effectively treated by administration of a psychostimulant. Low doses of the psychostimulant significantly increases the percentage of correctly pronounced intelligible syllables or words and the ability to more intelligibly communicate. The improvement in speech persists after cessation of or prior to continued psychostimulant treatment.Type: ApplicationFiled: August 6, 2014Publication date: December 4, 2014Inventors: Bruce Roseman, Gilla Kaplan
-
Publication number: 20140350118Abstract: The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof.Type: ApplicationFiled: June 5, 2014Publication date: November 27, 2014Inventors: Bhushan Hardas, Donna Dalton
-
Intrathecal or epidural administration of 3-[(1S,25)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
Patent number: 8895623Abstract: The present invention relates to a method of providing pain management in a subject wherein the administration of the composition does not result in any non-central nervous system mediated systemic effect in the subject. In particular, the present invention relates to a method of administering 3-[(1S,2S)-3-(dimethylamino)-1-ethyl-2-methyl-propyl]-phenol in a space that is void of thrombocytes.Type: GrantFiled: July 27, 2012Date of Patent: November 25, 2014Assignee: Gruenenthal GmbHInventors: Petra Bloms-Funke, Derek John Saunders, Eric Lang -
Publication number: 20140343162Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.Type: ApplicationFiled: July 30, 2014Publication date: November 20, 2014Inventors: Berten Ceulemens, Lieven Lagae
-
Publication number: 20140343160Abstract: Transdermal drug delivery patches and methods of their production are described. The patches can be made such that they accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.Type: ApplicationFiled: June 13, 2014Publication date: November 20, 2014Inventors: Sharad K. Govil, Ludwig J. Weimann
-
Publication number: 20140343161Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.Type: ApplicationFiled: July 30, 2014Publication date: November 20, 2014Inventors: Berten Ceulemens, Lieven Lagae
-
Publication number: 20140343044Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.Type: ApplicationFiled: July 30, 2014Publication date: November 20, 2014Inventors: Berten Ceulemens, Lieven Lagae
-
Patent number: 8889194Abstract: Disclosed is a compound and methods for use by an individual attempting to reduce or cease tobacco smoking or one exposed to environmental tobacco smoke. The compound includes a first component blocking nicotine receptor sites to reduce nicotine cravings or withdrawal symptoms, a second component increasing serotonin levels and acting synergistically with the first component to reduce nicotine cravings or withdrawal symptoms, assisting in maintaining body weight and reducing increased stress and anxiety, and a third component acting synergistically with the first and/or second component to reduce nicotine cravings or withdrawal symptoms, maintain body weight, and/or reduce increased stress and anxiety. The third component comprises a supplement that replenishes depleted body substance(s), repairs damaged body substance(s), and/or ameliorates the impaired function of body substance(s). Some combination of the first, second, and third component alters the perceived taste of tobacco smoke.Type: GrantFiled: September 29, 2010Date of Patent: November 18, 2014Inventor: Harlan Clayton Bieley
-
Publication number: 20140336265Abstract: A compound of formula I: wherein X is O, S, SO or SO2; R1 is halogen, trihalomethyl, —OH, C1-7alkyl, C1-4alkoxy, trifluoromethoxy, phenoxy, cyclohexylmethyloxy, pyridylmethoxy, cinnamyloxy, naphthylmethoxy, phenoxymethyl, —CH2—OH, —CH2—CH2—OH, C1-4alkylthio, C1-4alkylsulfinyl, C1-4alkylsulfonyl, benzylthio, acetyl, nitro or cyano, or phenyl, phenylC1-4alkyl or phenyl-C1-4alkoxy each phenyl group thereof being optionally substituted by halogen, CF3, C1-4alkyl or C1-4alkoxy; R2 is H, halogen, trihalomethyl, C1-4alkoxy, phenethyl or benzyloxy; R3 H, halogen, CF3, OH, C1-7alkyl, C1-4alkoxy, benzyloxy, phenyl or C1-4alkoxymethyl; each of R4 and R5, independently is H or a residue of formula (a) wherein each of R8 and R9, independently, is H or C1-4alkyl optionally substituted by halogen; and n is an integer from 1 to 4; or a pharmaceutically acceptable salt, hydrate, solvate, isomer or prodrug thereof; or a compound of formula II wherein R1a is halogen, trihalomethyl, C1-4alkyl, C1-4alkoxType: ApplicationFiled: July 28, 2014Publication date: November 13, 2014Applicant: NOVARTIS AGInventors: Peter Gergely, Erik Wallstroem, Eric Legangneux
-
Publication number: 20140336264Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.Type: ApplicationFiled: March 14, 2014Publication date: November 13, 2014Applicant: TONIX PHARMACEUTICALS, INC.Inventors: Marino Nebuloni, Patrizia Colombo
-
Publication number: 20140336216Abstract: Provided herein are compounds capable of activating GPR139. Also provided are methods of increasing and decreasing the activity of GPR139. Methods of using the identified compounds to modulate GPR139 activity or conditions that may be affected by GPR139 activity are also disclosed.Type: ApplicationFiled: March 14, 2014Publication date: November 13, 2014Applicant: Janssen Pharmaceutica NVInventors: Curt A. Dvorak, Changlu Liu, Chester Kuei
-
Patent number: 8883815Abstract: Cerebral palsy impaired speech in children and adolescents are effectively treated by administration of a psychostimulant. Low doses of the psychostimulant significantly increases the percentage of correctly pronounced intelligible syllables or words and the ability to more intelligibly communicate. The improvement in speech persists after cessation of or prior to continued psychostimulant treatment.Type: GrantFiled: October 22, 2013Date of Patent: November 11, 2014Assignee: Gilrose Pharmaceuticals, LLCInventors: Bruce Roseman, Gilla Kaplan
-
Publication number: 20140329908Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.Type: ApplicationFiled: May 3, 2013Publication date: November 6, 2014Inventors: Berten Ceulemens, Lieven Lagae
-
Publication number: 20140323423Abstract: Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible.Type: ApplicationFiled: May 2, 2014Publication date: October 30, 2014Applicant: Chrono Therapeutics, Inc.Inventors: Guy DiPierro, Steven A. Giannos
-
Publication number: 20140322298Abstract: Described are transdermal drug delivery compositions comprising amphetamine, methods of making transdermal drug delivery compositions comprising amphetamine, and therapeutic methods of using them. In specific embodiments, the compositions are free of components with moieties that are reactive with amphetamine. In specific embodiments, the compositions are manufactured using solvents free of components with moieties that are reactive with amphetamine. Therapeutic methods using the compositions also are described.Type: ApplicationFiled: March 13, 2014Publication date: October 30, 2014Applicant: NOVEN PHARMACEUTICALS, INC.Inventors: Viet Nguyen, Jun LlAO, Prashant PATEL
-
Publication number: 20140322293Abstract: The biodegradable drug delivery systems described here are formulated for implantation into the nail unit and its surrounding tissues for the treatment of various nail unit conditions. The systems include non-temperature dependent phase change compositions that may be formulated as solutions, solids, semisolids, microparticles, or crystals.Type: ApplicationFiled: April 29, 2014Publication date: October 30, 2014Applicant: Hallux, Inc.Inventors: Frank Kochinke, Corinne Bright
-
Publication number: 20140322323Abstract: The invention relates to a pharmaceutical dosage form, preferably with controlled release of a pharmacologically active compound (A) contained therein, the pharmaceutical dosage form very preferably being tamper-resistant and most preferably having a breaking strength B1 of at least 500 N in direction of extension E1 and having a breaking strength B2 of less than 500 N in direction of extension E2.Type: ApplicationFiled: April 25, 2014Publication date: October 30, 2014Applicant: GRÜNENTHAL GMBHInventors: EUGEEN MARIE JOZEF JANS, FILIP RENÉ IRENA KIEKENS, JODY FIRMIN MARCELINE VOORSPOELS, ANNE FAURE, IRIS ZIEGLER, ELISABETH ARKENAU-MARIC, LUTZ BARNSCHEID, JOHANNES BARTHOLOMÄUS, MARC FREVEL, ERIC GALIA, ANDREA SCHÜESSELE
-
Publication number: 20140324016Abstract: A method and apparatus for treatment of cardiac and renal diseases associated with the elevated sympathetic renal nerve activity by implanting a device to block the renal nerve signals to and from the kidney. The device can be a drug pump or a drug eluding implant for targeted delivery of a nerve-blocking agent to the periarterial space of the renal artery.Type: ApplicationFiled: March 21, 2014Publication date: October 30, 2014Applicant: Medtronic Ardian Luxembourg S.a.r.l.Inventors: Mark Gelfand, Howard R. Levin
-
Publication number: 20140323581Abstract: The invention is directed to methods to identify predisposition or risk to develop Parkinson's disease, methods to identify agents which have therapeutic effect on Parkinson's disease, and methods to determine the therapeutic effect of an agent in a subject suffering from Parkinson's disease, and to kits and reagents for carrying out the methods of the invention.Type: ApplicationFiled: December 5, 2012Publication date: October 30, 2014Inventors: Asa Abeliovich, Hervé Rhinn
-
Publication number: 20140323580Abstract: A pharmaceutical composition liquid dosage form of phentermine is provided, the dosage form including a liquid carrier and suspended or dissolved therein one or more pharmaceutically active ingredient selected from phentermine, salts and bases thereof. Also provided is a method of administering phentermine to an obese patient in need thereof and for appetite suppression or related conditions.Type: ApplicationFiled: July 3, 2014Publication date: October 30, 2014Inventors: Leneri Du Toit, Eduan Stoltz, Marina Coetzee
-
Patent number: 8865733Abstract: A treatment is described for diseases with symptoms that can include fatigue, muscle aches and spasms, weakness, demylenation, and nerve pain. Diseases can include fibromyalgia, depression, and auto-immune and immuno-suppressive diseases, such as MS. The treatment comprises about 1-10 mg naltrexone, at least about 20 ?g vitamin B12, at least about 5 mg vitamin B6, at least about 2 mg coenzyme Q, and preferably at least one ancillary medication selected from the group consisting of diazepam, cyclcobenzaprine, clonazepam, alprazolam, 9-tetrahydrocannibinol, fumarate, caffeine, and combinations thereof. The treatment can be administered orally, and can decrease mental and physical symptoms such as, for example, fatigue, gait problems, visual dysfunction, and pain while improving cognitive skills.Type: GrantFiled: October 31, 2009Date of Patent: October 21, 2014Assignee: Altman Enterprises, LLCInventor: Mitchell S. Felder
-
Publication number: 20140303257Abstract: Provided is a method for treating solid tumors, e.g tumor invasiveness, and particularly inhibiting or controlling deregulated angiogenesis, using a sphingosine-1-phosphate receptor agonist, optionally in combination with a chemotherapeutic agent. The invention also comprises a combination of a sphingosine-1-phosphate receptor agonist with a chemotherapeutic agent.Type: ApplicationFiled: June 23, 2014Publication date: October 9, 2014Applicant: Novartis AGInventors: Thomas Baumruker, Volker Brinkmann, Kenneth Richard La Montagne, Peter T. Lassota, Diane Mechtcheriakova, Jeanette Majorie Wood
-
Patent number: 8853278Abstract: Compounds, compositions, and methods comprising a polyamine compound are described, which may be used to kill, disperse, treat, reduce biofilms, and/or inhibit or substantially prevent biofilm formation. In certain aspects, the present invention relates to compounds, compositions, and methods comprising polyamine compounds that have antimicrobial or dispersing activity against a variety of bacterial strains capable of forming biofilms.Type: GrantFiled: November 8, 2013Date of Patent: October 7, 2014Assignees: Curza Global, LLC, University of Utah Research FoundationInventors: Ryan Looper, Dustin Williams, Sujeevini Jeyapalina, Travis Haussener, Paul R. Sebahar, Hari Kanna Reddy
-
Publication number: 20140296346Abstract: A hitherto unknown crystalline form of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.Type: ApplicationFiled: June 13, 2014Publication date: October 2, 2014Inventors: Andreas FISCHER, Helmut BUSCHMANN, Michael GRUSS, Dagmar LISCHKE
-
Publication number: 20140296339Abstract: Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.Type: ApplicationFiled: June 17, 2014Publication date: October 2, 2014Inventors: Thomas G. Gant, Sepehr Sarshar
-
Patent number: 8846765Abstract: A pharmaceutical combination comprising as components (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and (b) at least one NMDA-antagonist, a pharmaceutical formulation and a dosage form comprising such a combination, and a method of treating pain, e.g. inflammatory pain or neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, with component (a) being administered either before or after component (b), and with components (a) or (b) being administered to the mammal either via the same pathway of administration or via different pathways of administration.Type: GrantFiled: June 14, 2011Date of Patent: September 30, 2014Assignee: Gruenenthal GmbHInventors: Klaus Schiene, Petra Bloms-Funke
-
Publication number: 20140288078Abstract: The present invention relates to methods of treating multidrug resistance in cancerous cells with phosphodiesterase (PDE) inhibitors, e.g., PDE5 inhibitors. More specifically, the invention relates to methods of treating multidrug resistance that arises, e.g., during administration of chemotherapeutic/antineoplastic (anticancer) agents for treatment of cancer, with a PDE5 inhibitor (e.g., sildenafil, vardenafil, and tadalafil). The invention also relates to methods of treating cancer, e.g., multidrug resistant cancer, using a PDE5 inhibitor in combination with an antineoplastic therapeutic agent. Further, the invention relates to pharmaceutical compositions for treating multidrug resistant cancers comprising a PDE5 inhibitor, or a combination of a PDE5 inhibitor and an antineoplastic agent.Type: ApplicationFiled: March 17, 2014Publication date: September 25, 2014Applicant: St. John's UniversityInventors: Zhe-Sheng CHEN, Zhi SHI, Charles R. ASHBY
-
Publication number: 20140288117Abstract: The subject invention provides materials and methods for treating neurodegenerative diseases. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat Parkinson's Disease and/or complications associated with Parkinson's Disease. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of Parkinson's Disease in an at-risk patient and/or treat or prevent the onset of Parkinson's Disease-associated symptoms.Type: ApplicationFiled: June 5, 2014Publication date: September 25, 2014Inventor: Bill Piu CHAN
-
Patent number: 8840923Abstract: Slow-release excipients which comprise an association of at least one glycogen and at least one alginate with an alkaline-earth metal salt are useful for the preparation of slow-release pharmaceutical formulations.Type: GrantFiled: December 23, 2008Date of Patent: September 23, 2014Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.Inventors: Vincenzo Russo, Elisa Liberati, Nicola Cazzolla, Leonardo Marchitto, Lorella Ragni
-
Publication number: 20140271865Abstract: Described are transdermal drug delivery compositions comprising amphetamine, methods of making them and therapeutic methods using them. The compositions are provided in a flexible, finite form (e.g. “patch”-type systems) and comprise a polymer matrix that includes amphetamine and an acrylic block copolymer.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: NOVEN PHARMACEUTICALS, INC.Inventors: Robert Lambert, Weijun Lu, Jun Liao
-
Publication number: 20140275147Abstract: The present disclosure provides compositions (e.g., extended release compositions) which exhibit a desirable pharmacokinetic profile of an active agent while providing reduced dissolution sample variability, e.g., in the form of reduced inter-capsule variability and/or a reduction in storage-time dependent change in mean release of the active agent from the composition. Related methods of making and administering the disclosed compositions and formulations are also provided.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Inventors: Su Il Yum, Wendy Chao, Huey-Ching Su, Roger Fu, Michael S. Zamloot, Karl Bratin, Ravi M. Shanker
-
Publication number: 20140256823Abstract: Disclosed are preparations and formulations of high thermodynamic activity lipophilic associations (LA), in which there is pairing between an ionizable pharmaceutical agent and a lipophilic species having ionic characteristics opposite to that of the pharmaceutical agent. Such lipophilic associations manifest high thermodynamic activity, as evidenced by their being predominantly in a liquid phase at room temperature or solvated in a lower-than-water dielectric solvent. Further the pharmaceutical agent being solubilized means that dissolution is not rate limiting to transmucosal absorption. This LA or LA-solvate is formulated into a low dielectric dosage form, from whence, upon the dosage form's hydration, the pharmaceutical agent is driven through the mucosal tissue and into systemic circulation. The invention therefore provides an enhanced transmucosal drug delivery system for ionizable pharmaceutical agents at or near physiological pH.Type: ApplicationFiled: March 10, 2014Publication date: September 11, 2014Inventor: John McCarty
-
Publication number: 20140256746Abstract: A method and composition for treating osteoarthritis with ion-channel regulators is disclosed. The ion-channel regulators are used alone or in combination with other osteoarthritis treatment agents, including but not limited to injectable agents such as viscosupplements and steroids. A composition comprising one or more ion-channel regulator(s) and one or more osteoarthritis treatment agent(s) is also disclosed.Type: ApplicationFiled: September 10, 2013Publication date: September 11, 2014Applicant: CALOSYN PHARMA, INC.Inventor: David D. Waddell
-
Publication number: 20140248330Abstract: A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent.Type: ApplicationFiled: April 4, 2014Publication date: September 4, 2014Applicant: Noven Pharmaceuticals, Inc.Inventor: David Kanios
-
Publication number: 20140249180Abstract: A tau aggregation inhibitor reduces tau aggregation in cells. The tau aggregation inhibitor can include a catechol structure-containing compound or a salt thereof, and the catechol structure-containing compound can be one of isoprenaline, dopamine, dobutamine, levodopa, levodopa/carbidopa, trimetoquinol, hexoprenaline, methyldopa, and droxidopa. One example of the catechol structure-containing compound is isoprenaline, which can be d-enantiomer of isoprenaline or d/l-racemic mixture of isoprenaline. Tauopathies to be prevented or treated by the inhibitor include AD, Down's syndrome, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy.Type: ApplicationFiled: October 3, 2012Publication date: September 4, 2014Applicants: National Center for Geriatrics and Gerontology, THE DOSHISHAInventors: Akihiko Takashima, Yoshiyuki Soeda, Hiroyuki Nagata, Yasuo Ihara, Tomohiro Miyasaka, Hachiro Sugimoto
-
Publication number: 20140243379Abstract: Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.Type: ApplicationFiled: May 7, 2014Publication date: August 28, 2014Applicant: MYLAN TECHNOLOGIES, INC.Inventors: Sharad K. Govil, Ludwig J. Weimann
-
Publication number: 20140235728Abstract: The present disclosure relates to polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same.Type: ApplicationFiled: April 23, 2014Publication date: August 21, 2014Applicants: Shandong Luye Pharmaceutical Co., Ltd.Inventors: Youxin Li, Wanhui Liu, Yang Lv, Guanhua Du, Qingguo Meng, Mina Yang, Fengmei Zhou, Ju Li, Xuemei Zhang
-
Publication number: 20140234402Abstract: Compositions and methods for treating systemic diseases by intravenous administration of formulations of synthesized curcumin (diferuloylmethane) and concomitantly a calcium channel blocker to human subjects with neoplastic and neurodegenerative diseases are disclosed herein. The diseases are treated by prolonged administration of sub-optimal doses of liposomal curcumin or polymeric nanocurcumin or the sustained release curcumin from PLGA nanocurcumin at dosages below systemic hemolytic thresholds concomitantly with or without calcium channel blockers.Type: ApplicationFiled: April 30, 2014Publication date: August 21, 2014Applicant: SignPath Pharma Inc.Inventor: Lawrence Helson
-
Publication number: 20140228380Abstract: The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.Type: ApplicationFiled: August 2, 2013Publication date: August 14, 2014Applicants: University of Medicine and Dentistry New Jersey Medical School, Philadelphia Health & Education Corporation d/b/a Drexel University College of MedicineInventors: Sandhya Kortagere, Eldo V. Kuzhikandahil
-
Publication number: 20140228355Abstract: The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.Type: ApplicationFiled: February 11, 2013Publication date: August 14, 2014Applicants: University of Medicine and Dentistry New Jersey Medical School, Philadelphia Health & Education Corporation d/b/a Drexel University College of MedicineInventors: Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine, University of Medicine and Dentistry New Jersey Medical School
-
Publication number: 20140227197Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by a prolonged release.Type: ApplicationFiled: April 17, 2014Publication date: August 14, 2014Inventors: David Lickrish, Feng Zhang
-
Publication number: 20140228402Abstract: The invention relates to a combination which comprises fingolimod and at least antidepressant compound.Type: ApplicationFiled: September 7, 2012Publication date: August 14, 2014Applicant: Novartis AGInventors: Matthias Meergans, Ferenc Tracik, Katrin Schuh
-
Patent number: 8802636Abstract: The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.Type: GrantFiled: January 6, 2010Date of Patent: August 12, 2014Assignee: Vivus, Inc.Inventor: Thomas Najarian
-
Publication number: 20140221499Abstract: Provided herein is method for controlling a rodent. The method comprises contacting the rodent with a compound which is a ligand for an olfactory trace amine associated receptor (TAAR) or a composition comprising such a molecule. The compound can be a biogenic amine.Type: ApplicationFiled: April 26, 2012Publication date: August 7, 2014Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Stephen D. Liberles, David M. Ferrero
-
Publication number: 20140221489Abstract: A method of eliminating or significantly decreasing shifts between dyskinesia and bradykinesia in a patient suffering from an advanced stage of Parkinson's Disease comprises for a predetermined time period intravenously, subcutaneously or intrathekally administering to the patient by continuous infusion a stable and therapeutically acceptable solution comprising at least 5 mg/ml of Levodopa.Type: ApplicationFiled: April 14, 2014Publication date: August 7, 2014Applicant: Dizlin Medical Design ABInventor: Nil Dizdar Segrell
-
Publication number: 20140213658Abstract: The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof.Type: ApplicationFiled: January 31, 2013Publication date: July 31, 2014Applicant: MERZ PHARMACEUTICALS, LLCInventors: Bhushan Hardas, Donna Dalton
-
Publication number: 20140213617Abstract: Provided are alkynyl phenyl derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.Type: ApplicationFiled: January 23, 2014Publication date: July 31, 2014Applicant: ACUCELA INC.Inventors: Ian Leslie Scott, Vladimir Aleksandrovich Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Jennifer Gage, Feng Hong
-
Publication number: 20140206770Abstract: Disclosed is the use of at least one amine oxidase inhibitor for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal and to pharmaceutical compositions for controlling the androgen receptor-dependent gene expression, comprising an effective dose of at least one amine oxidase inhibitor suitable for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal.Type: ApplicationFiled: February 4, 2014Publication date: July 24, 2014Applicant: UNIVERSITAETSKLINIKUM FREIBURGInventors: Roland SCHUELE, Eric METZGER
-
Publication number: 20140194524Abstract: Cognitive impairments in humans with Alzheimer's disease are treated by administering a composition that includes an amphetamine compound. Memory, attention and executive function can be improved following administration of the amphetamine compound.Type: ApplicationFiled: December 13, 2013Publication date: July 10, 2014Applicant: Cognition Pharmaceuticals, LLCInventors: Mel H. Epstein, Kjesten A. Wiig, Mark F. Bear